ARTICLE | Company News
InNexus, NIH deal
June 7, 2010 7:00 AM UTC
InNexus and NIH's National Cancer Institute (NCI) will use InNexus' Dynamic Cross Linking (DXL) antibody technology to develop immunotoxins to treat cancer. Further terms were not disclosed. ...